Dennis Langer

Dennis Langer, listed as board member, has filed trades across 3 companies (mainly through SEC (Form 4)), most often in Myriad Genetics Inc, Dicerna Pharmaceuticals Inc and Quoin Pharmaceuticals, Ltd. Over a trading history stretching from 3 February 2016 to 27 August 2026, the count stands at 12 filings.

Market trades split into 1 purchase (€111k) and 3 sales (€541k). Sales outweigh purchases by €430k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 6 share grants and 2 option exercises.

The newest entry dates from 28 August 2026: a share grant of €153k, in Quoin Pharmaceuticals, Ltd. The clock since the last published purchase (15 October 2025) now reads 374 days. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.